Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
ExpreS2ion Biotech cuts Q2 loss, early HER2 data show immune response without safety concerns
ExpreS2ion Biotech reported a net loss of SEK 9.7m in the second quarter versus SEK 10m a year earlier, while the operating loss rose slightly to SEK 12m. Operating income increased to SEK 11.5m, driven by grants, and R&D expenses climbed to SEK 11.4m (+483%) as the HER2 program ES2B‑C001 was advanced. In the Phase I trial, 12 of 13 evaluable patients showed drug‑specific antibody responses with no new safety signals; a Phase II start is now expected in H2 2027. The company completed a rights issue and had SEK 34.4m in cash at quarter‑end, but remains operationally loss‑making and reliant on grant funding and partner interest. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 181,47K | 31,55% |
| Utile lordo | -916,18K | 3996,37% |
| Utile netto | -875,39K | 2,70% |
| EBITDA | -1,92 Mln | 89,44% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 240,71K € |
Numero di azioni | 2,55 Mln |
Massimo/minimo a 52 settimane | 2,04 € - 0,0878 € |
| Dividendi | No |
Beta | 2,21 |
Rapporto P/E | -0,15 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,91 |
Rapporto P/S | 0,70 |
Profilo aziendale
ExpreS2ion Biotech Holding AB (publ) entwickelt und produziert über ihre Tochtergesellschaft ExpreS2 ion Biotechnologies ApS in Dänemark komplexe Proteine für Impfstoffe und Diagnostika. Das Unternehmen entwickelt den Impfstoff COVID-19, der sich in Phase II der klinischen Prüfung befindet. Außerdem entwickelt es einen Grippe- und Brustkrebsimpfstoff, der sich in der klinischen Phase II befindet, sowie einen Malariaimpfstoff. Darüber hinaus lizenziert das Unternehmen seine ExpreS2-Plattform an Forschungsinstitute und Pharmaunternehmen. Die ExpreS2ion Biotech Holding AB (publ) wurde 2015 gegründet und hat ihren Sitz in Horsholm, Dänemark.
| Nome | EXPRES2ION BIOTECH HLDG |
| CEO | Bent U. Frandsen |
| Sede centrale | Helsingborg,
Danimarca |
| Sito web | |
| Quotazione in borsa | 13/05/2014 |
| Dipendenti | 19 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Sto | EXPRS2.ST |
Frankfurt | 5JD.F |
Stockholm | EXPRS2.ST |
München | 5JD.MU |
